Controlled trial of slowing of Kidney Disease progression From the Inhibition of Xanthine oxidase (CKD-FIX): A double-blind, randomised, placebo-controlled trial

点击翻译按钮获取中文摘要

Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.